Zung Amnon, Kori Michal
Pediatric Endocrinology Unit, Kaplan Medical Center, affiliated with the Hebrew University of Jerusalem, Rehovot, Israel.
J Pediatr Endocrinol Metab. 2012;25(1-2):131-7. doi: 10.1515/jpem.2011.360.
To assess the association between seroconversion and catch-up growth during the first year of a gluten-free diet (GFD) program in children with celiac disease (CD).
All prepubertal and biopsy-proven children diagnosed with CD between January 1999 and August 2009 were included in a retrospective study (n=55). Growth parameters and celiac antibodies were documented before and after 6 (period 1) and 12 months (period 2) of GFD, respectively.
Mean height velocity-standard deviation score (SDS) was significantly higher in period 1 compared with that in period 2 (2.90 +/- 3.20 vs. 0.20 +/- 2.08, p<0.001) irrespective of the serology status, with marginal difference in mean weight-SDS gain (p=0.074). Mean levels of height velocity-SDS and the weight-SDS gain were similar in the seropositive and seronegative groups in both periods of the study. Mean height-SDS and weight-SDS levels after 6 months were higher than those in baseline levels, both in seropositive (-0.47 +/- 0.91 vs. -0.82 +/- 0.82, p<0.001 and -0.59 +/- 1.17 vs. -1.11 +/- 1.33, p<0.001, respectively) and seronegative patients (-1.02 +/- 1.14 vs. -1.50 +/- 1.12, p<0.001 and -1.19 +/- 1.27 vs. -1.45 +/- 1.40, p=0.048, respectively). These growth parameters were higher at the end compared with the beginning of period 2, but only in seropositive patients.
The most remarkable catch-up growth in children with CD can be expected during the first 6 months of GFD, irrespective of the serology status.
评估乳糜泻（CD）患儿在无麸质饮食（GFD）计划第一年期间血清转化与追赶生长之间的关联。
1999年1月至2009年8月期间所有青春期前且经活检证实诊断为CD的儿童纳入一项回顾性研究（n = 55）。分别记录GFD 6个月（时期1）和12个月（时期2）前后的生长参数和乳糜泻抗体。
无论血清学状态如何，时期1的平均身高速度标准差评分（SDS）显著高于时期2（2.90±3.20对0.20±2.08，p<0.001），平均体重SDS增加存在微小差异（p = 0.074）。在研究的两个时期中，血清阳性和血清阴性组的平均身高速度SDS和体重SDS增加水平相似。6个月后的平均身高SDS和体重SDS水平均高于基线水平，血清阳性患者（分别为-0.47±0.91对-0.82±0.82，p<0.001和-0.59±1.17对-1.11±1.33，p<0.001）和血清阴性患者（分别为-1.02±1.14对-1.50±1.12，p<0.001和-1.19±1.27对-1.45±1.40，p = 0.048）均如此。这些生长参数在时期2结束时高于开始时，但仅在血清阳性患者中如此。
无论血清学状态如何，CD患儿在GFD的前6个月有望出现最显著的追赶生长。
